Company: AZN
Filing Date: 2025-10-20
Form Type: 6-K
Source: 0001654954-25-011943
Chunk: 7

Company: ASTRAZENECA PLC
Filing Date: 2025-10-20
Form: 6-K
Chunk 7
---
 or Subacute Cutaneous Lupus Erythematosus (LAVENDER). Available at: https://clinicaltrials.gov/study/NCT06015737 . [Last accessed: October 2025].

29. Clinicaltrials.gov. A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis) (JASMINE). Available at: https://clinicaltrials.gov/study/NCT06455449 . [Last accessed: October 2025].

30. Clinicaltrials.gov. Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY). Available at: https://clinicaltrials.gov/study/NCT05925803 . [Last accessed: October 2025].

31. ClinicalTrials.gov. Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis (IRIS). Available at: https://www.clinicaltrials.gov/ct2/show/NCT05138133 . [Last accessed: October 2025].

#### Matthew Bowden

#### Company Secretary

#### AstraZeneca PLC
<div align='center'>SIGNATURES</div>

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| AstraZeneca 
 PLC         |

Date:20 October 2025

| By: /s/           
 Matthew Bowden    |
| Name:             
 Matthew Bowden    |
| Title:            
 Company Secretary |